Navigation Links
Stemline Therapeutics Raises $12.5 Million
Date:4/9/2008

Proceeds to advance oncology therapeutics targeting cancer stem cells

NEW YORK, April 9, 2008 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that it has completed a $12.5 million round of financing with healthcare funds managed by Pequot Capital Management, Inc.

Stemline's CEO, Ivan Bergstein, MD, said. "We are very pleased to have consummated this transaction with a fund of this caliber. The capital provides us with significant runway to advance our clinical program, while continuing to build out our pipeline, discovery platform, and comprehensive IP estate. Moreover, this financing allows us to continue to strengthen our leadership position in the rapidly emerging cancer stem cell field."

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human trial. In addition, Stemline is developing a portfolio of compounds directed at this and other high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has also built a robust discovery platform called "StemScreen(R)" which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. For more information, please visit the Company's website at http://www.stemline.com.


'/>"/>
SOURCE Stemline Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
2. Amsterdam Molecular Therapeutics Part of Next Biotech Index
3. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
4. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
5. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
6. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
7. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
8. Mercury Therapeutics Patents Filed
9. Cell Therapeutics, Inc. Announces Filing of Form 10-K
10. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
11. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts ... they believe could be a new and helpful biomarker for malignant pleural mesothelioma. ... here to read it now. , Biomarkers are components in the blood, ...
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
Breaking Biology Technology:
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):